We assessed the efficacy and safety of sodium-glucose co-transporter-2 (SGLT2) or dipeptidyl peptidase-4 (DPP-4) inhibitor monotherapies in adolescents and young adults with T2D not on active therapy. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.